Skip to content

Study · Animal study (in vivo) · rat · 2001

1 result

Protective effect of melanocortin peptides in rat myocardial ischemia.

Bazzani C, Guarini S, Botticelli AR, Zaffe D, Tomasi A, Bini A, Cainazzo MM, Ferrazza G, Mioni C, Bertolini A

The Journal of pharmacology and experimental therapeutics1 Jun 2001Cited by 42 (Europe PMC)

PMID11356932 (opens in a new tab)DOI10.1016/s0022-3565(24)29636-1 (opens in a new tab)PepBankPUB-11356932
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with permanent coronary occlusion, subcutaneous NDP-MSH significantly increased the amount of healthy myocardial tissue versus saline.

    In plain wordsIn rats with a blocked heart artery, NDP-MSH left more healthy heart tissue than saline.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseAmount of healthy myocardial tissue 72 h after permanent coronary occlusion
    Study

    ratn: not reported in source

    anesthetized rats, permanent coronary occlusion
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.27 mg/kg every 12 h · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    In rats subjected to permanent coronary occlusion, the amount of healthy myocardial tissue was much reduced in saline-treated rats, while in rats treated s.c. with NDP-MSH (0.27 mg/kg every 12 h) it was significantly higher.
    1 context sentence
    Summary · context
    Ischemia was produced by ligature of the left anterior descending coronary artery.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.